| Characteristic . | Total n = 98 . |
|---|---|
| Age, median (range), y | 62.5 (20–85) |
| Sex, No. (%) | … |
| Male | 33 (33.7) |
| Female | 65 (66.3) |
| Race, No. (%) | … |
| White | 84 (85.7) |
| Black or African American | 8 (8.2) |
| Other or not reported | 6 (6.1) |
| Body mass index, median (range), kg/m2 | 26.33 (16.37–41.78) |
| Weight >90 kg, No. (%) | 28 (28.6) |
| Albumin, median (range), g/dL | 3.1 (1.7–4.8) |
| Albumin ≤3 g/dL, No. (%) | 47 (48.0) |
| Albumin >3 g/dL, No. (%) | 51 (52.0) |
| Malignancy, No. (%) | … |
| Acute myeloid leukemia | 47 (48.0) |
| Myelodysplastic syndrome | 15 (15.3) |
| Lymphoma | 9 (9.2) |
| Myeloproliferative neoplasms | 6 (6.1) |
| Acute lymphocytic leukemia | 4 (4.1) |
| Multiple myeloma | 1 (1.0) |
| Other | 17 (17.3) |
| Stem cell transplant and cellular therapies | … |
| Allogeneic | 49 (50.0) |
| Chimeric antigen receptor–T therapy | 10 (10.2) |
| Stem cell+ CAR-T therapy | 2 (2.0) |
| Acute gastrointestinal graft-vs-host disease, No. (%) | 10 (10.2) |
| Interacting drug—any, No. (%) | 82 (83.7) |
| Proton pump inhibitor, No. (%) | 51 (52.0) |
| Diarrhea, No. (%) | 21 (21.4) |
| Indication for posaconazole, No. (%) | … |
| Treatment | 76 (77.6) |
| Prophylaxis | 22 (22.4) |
| Infections definition, No. (%) | … |
| Possible | 44 (44.9) |
| Probable | 24 (24.5) |
| Proven | 5 (5.1) |
| Not applicable (prophylaxis or undefined) | 25 (25.5) |
| Infection site, No. (%) | … |
| Pulmonary | 62 (63.3) |
| Rhino-cerebral | 7 (7.1) |
| Cutaneous | 5 (5.1) |
| Other | 2 (2.0) |
| Not applicable (prophylaxis) | 22 (22.4) |
| Organism isolated, No. (%) | 28 (28.6) |
| Characteristic . | Total n = 98 . |
|---|---|
| Age, median (range), y | 62.5 (20–85) |
| Sex, No. (%) | … |
| Male | 33 (33.7) |
| Female | 65 (66.3) |
| Race, No. (%) | … |
| White | 84 (85.7) |
| Black or African American | 8 (8.2) |
| Other or not reported | 6 (6.1) |
| Body mass index, median (range), kg/m2 | 26.33 (16.37–41.78) |
| Weight >90 kg, No. (%) | 28 (28.6) |
| Albumin, median (range), g/dL | 3.1 (1.7–4.8) |
| Albumin ≤3 g/dL, No. (%) | 47 (48.0) |
| Albumin >3 g/dL, No. (%) | 51 (52.0) |
| Malignancy, No. (%) | … |
| Acute myeloid leukemia | 47 (48.0) |
| Myelodysplastic syndrome | 15 (15.3) |
| Lymphoma | 9 (9.2) |
| Myeloproliferative neoplasms | 6 (6.1) |
| Acute lymphocytic leukemia | 4 (4.1) |
| Multiple myeloma | 1 (1.0) |
| Other | 17 (17.3) |
| Stem cell transplant and cellular therapies | … |
| Allogeneic | 49 (50.0) |
| Chimeric antigen receptor–T therapy | 10 (10.2) |
| Stem cell+ CAR-T therapy | 2 (2.0) |
| Acute gastrointestinal graft-vs-host disease, No. (%) | 10 (10.2) |
| Interacting drug—any, No. (%) | 82 (83.7) |
| Proton pump inhibitor, No. (%) | 51 (52.0) |
| Diarrhea, No. (%) | 21 (21.4) |
| Indication for posaconazole, No. (%) | … |
| Treatment | 76 (77.6) |
| Prophylaxis | 22 (22.4) |
| Infections definition, No. (%) | … |
| Possible | 44 (44.9) |
| Probable | 24 (24.5) |
| Proven | 5 (5.1) |
| Not applicable (prophylaxis or undefined) | 25 (25.5) |
| Infection site, No. (%) | … |
| Pulmonary | 62 (63.3) |
| Rhino-cerebral | 7 (7.1) |
| Cutaneous | 5 (5.1) |
| Other | 2 (2.0) |
| Not applicable (prophylaxis) | 22 (22.4) |
| Organism isolated, No. (%) | 28 (28.6) |
| Characteristic . | Total n = 98 . |
|---|---|
| Age, median (range), y | 62.5 (20–85) |
| Sex, No. (%) | … |
| Male | 33 (33.7) |
| Female | 65 (66.3) |
| Race, No. (%) | … |
| White | 84 (85.7) |
| Black or African American | 8 (8.2) |
| Other or not reported | 6 (6.1) |
| Body mass index, median (range), kg/m2 | 26.33 (16.37–41.78) |
| Weight >90 kg, No. (%) | 28 (28.6) |
| Albumin, median (range), g/dL | 3.1 (1.7–4.8) |
| Albumin ≤3 g/dL, No. (%) | 47 (48.0) |
| Albumin >3 g/dL, No. (%) | 51 (52.0) |
| Malignancy, No. (%) | … |
| Acute myeloid leukemia | 47 (48.0) |
| Myelodysplastic syndrome | 15 (15.3) |
| Lymphoma | 9 (9.2) |
| Myeloproliferative neoplasms | 6 (6.1) |
| Acute lymphocytic leukemia | 4 (4.1) |
| Multiple myeloma | 1 (1.0) |
| Other | 17 (17.3) |
| Stem cell transplant and cellular therapies | … |
| Allogeneic | 49 (50.0) |
| Chimeric antigen receptor–T therapy | 10 (10.2) |
| Stem cell+ CAR-T therapy | 2 (2.0) |
| Acute gastrointestinal graft-vs-host disease, No. (%) | 10 (10.2) |
| Interacting drug—any, No. (%) | 82 (83.7) |
| Proton pump inhibitor, No. (%) | 51 (52.0) |
| Diarrhea, No. (%) | 21 (21.4) |
| Indication for posaconazole, No. (%) | … |
| Treatment | 76 (77.6) |
| Prophylaxis | 22 (22.4) |
| Infections definition, No. (%) | … |
| Possible | 44 (44.9) |
| Probable | 24 (24.5) |
| Proven | 5 (5.1) |
| Not applicable (prophylaxis or undefined) | 25 (25.5) |
| Infection site, No. (%) | … |
| Pulmonary | 62 (63.3) |
| Rhino-cerebral | 7 (7.1) |
| Cutaneous | 5 (5.1) |
| Other | 2 (2.0) |
| Not applicable (prophylaxis) | 22 (22.4) |
| Organism isolated, No. (%) | 28 (28.6) |
| Characteristic . | Total n = 98 . |
|---|---|
| Age, median (range), y | 62.5 (20–85) |
| Sex, No. (%) | … |
| Male | 33 (33.7) |
| Female | 65 (66.3) |
| Race, No. (%) | … |
| White | 84 (85.7) |
| Black or African American | 8 (8.2) |
| Other or not reported | 6 (6.1) |
| Body mass index, median (range), kg/m2 | 26.33 (16.37–41.78) |
| Weight >90 kg, No. (%) | 28 (28.6) |
| Albumin, median (range), g/dL | 3.1 (1.7–4.8) |
| Albumin ≤3 g/dL, No. (%) | 47 (48.0) |
| Albumin >3 g/dL, No. (%) | 51 (52.0) |
| Malignancy, No. (%) | … |
| Acute myeloid leukemia | 47 (48.0) |
| Myelodysplastic syndrome | 15 (15.3) |
| Lymphoma | 9 (9.2) |
| Myeloproliferative neoplasms | 6 (6.1) |
| Acute lymphocytic leukemia | 4 (4.1) |
| Multiple myeloma | 1 (1.0) |
| Other | 17 (17.3) |
| Stem cell transplant and cellular therapies | … |
| Allogeneic | 49 (50.0) |
| Chimeric antigen receptor–T therapy | 10 (10.2) |
| Stem cell+ CAR-T therapy | 2 (2.0) |
| Acute gastrointestinal graft-vs-host disease, No. (%) | 10 (10.2) |
| Interacting drug—any, No. (%) | 82 (83.7) |
| Proton pump inhibitor, No. (%) | 51 (52.0) |
| Diarrhea, No. (%) | 21 (21.4) |
| Indication for posaconazole, No. (%) | … |
| Treatment | 76 (77.6) |
| Prophylaxis | 22 (22.4) |
| Infections definition, No. (%) | … |
| Possible | 44 (44.9) |
| Probable | 24 (24.5) |
| Proven | 5 (5.1) |
| Not applicable (prophylaxis or undefined) | 25 (25.5) |
| Infection site, No. (%) | … |
| Pulmonary | 62 (63.3) |
| Rhino-cerebral | 7 (7.1) |
| Cutaneous | 5 (5.1) |
| Other | 2 (2.0) |
| Not applicable (prophylaxis) | 22 (22.4) |
| Organism isolated, No. (%) | 28 (28.6) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
